Autolus Other Current Assets from 2010 to 2024

AUTL Stock  USD 4.48  0.08  1.75%   
Autolus Therapeutics Other Current Assets yearly trend continues to be quite stable with very little volatility. The value of Other Current Assets are projected to decrease to about 99.8 K. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2016-09-30
Previous Quarter
127 K
Current Value
35.7 M
Quarterly Volatility
7.9 M
 
Covid
Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 7.2 M or Total Revenue of 281.2 K, as well as many exotic indicators such as Price To Sales Ratio of 436, Dividend Yield of 0.0 or PTB Ratio of 10.55. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
  
This module can also supplement Autolus Therapeutics' financial leverage analysis and stock options assessment as well as various Autolus Therapeutics Technical models . Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Latest Autolus Therapeutics' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of Autolus Therapeutics over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. Autolus Therapeutics' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Autolus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

Autolus Other Current Assets Regression Statistics

Arithmetic Mean5,487,970
Geometric Mean180,223
Coefficient Of Variation254.70
Mean Deviation9,126,008
Median105,000
Standard Deviation13,977,677
Sample Variance195.4T
Range43.7M
R-Value0.30
Mean Square Error190.9T
R-Squared0.09
Significance0.27
Slope952,355
Total Sum of Squares2735.3T

Autolus Other Current Assets History

202499.8 K
202235.7 M
2021203 K
2020240 K
201943.7 M
2018105 K
2017717 K

About Autolus Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Autolus Therapeutics income statement, its balance sheet, and the statement of cash flows. Autolus Therapeutics investors use historical funamental indicators, such as Autolus Therapeutics's Other Current Assets, to determine how well the company is positioned to perform in the future. Although Autolus Therapeutics investors may use each financial statement separately, they are all related. The changes in Autolus Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Autolus Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Autolus Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Autolus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Assets105 K99.8 K
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Autolus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Autolus Therapeutics' short interest history, or implied volatility extrapolated from Autolus Therapeutics options trading.

Pair Trading with Autolus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Autolus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Autolus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Autolus Stock

  0.66ELYM Eliem TherapeuticsPairCorr
  0.42PAHC Phibro Animal Health Financial Report 1st of May 2024 PairCorr
  0.41ANIP ANI Pharmaceuticals Financial Report 13th of May 2024 PairCorr
The ability to find closely correlated positions to Autolus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Autolus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Autolus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Autolus Therapeutics to buy it.
The correlation of Autolus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Autolus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Autolus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Autolus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Autolus Stock analysis

When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
CEOs Directory
Screen CEOs from public companies around the world
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.20)
Revenue Per Share
0.01
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.25)
Return On Equity
(1.02)
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.